Testing an MBI for Smoking Cessation and Alcohol Use Among Cancer Survivors
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorH. Lee Moffitt Cancer Center and Research Institute
About this trial
This study will examine the efficacy of Mindfulness-Based Relapse Prevention for Smoking and Alcohol (MBRP-SA) compared to standard care among cancer survivors who smoke cigarettes and engage in at-risk alcohol use. Investigators will evaluate implementation outcomes through structured stakeholder interviews across medical centers, cancer-focused organizations, and community-based programs in Florida, and will conduct a cost-assessment and an incremental cost-effectiveness analysis of the two conditions.
Eligibility criteria
Qualifiers
≥18 years old
History of a cancer diagnosis at any point in lifetime
Smoked ≥1 cigarette/day in past month
At least one binge drinking episode in past month or exceeds weekly drinking limits
Disqualifiers
Pregnancy or lactation
Active psychotic disorder
History of severe alcohol withdrawal
Current use of tobacco cessation medication or other treatments to quit smoking
Trial design
Treatments tested in this trial
- Mindfulness-Based Relapse Prevention for Smoking and Alcohol (MBRP-SA)
- Quitline Support
Treatment groups
600 Participants
are divided into 2 treatment groupsSponsors and collaborators
H. Lee Moffitt Cancer Center and Research Institute
Lead sponsor
Florida Biomedical Research Program - James & Esther King
Collaborator
Source ClinicalTrials.gov